ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
暂无分享,去创建一个
Valerie A Longo | Jason T Giurleo | S. Larson | J. Carrasquillo | D. Veach | G. Thurston | W. Olson | P. Zanzonico | S. Cheal | E. K. Fung | S. Ruan | J. Kirshner | B. Punzalan | M. Kelly | Jason T. Giurleo | Amy Han | G. Ehrlich | Jiong Wu
[1] P. Fraker,et al. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.
[2] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[3] E. Lengyel,et al. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. , 2017, Cancer research.
[4] S. Larson,et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling , 2016, EJNMMI Research.
[5] J. Damiano,et al. Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer , 2013, Clinical Cancer Research.
[6] Neal Rosen,et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.
[7] Jason T Giurleo,et al. Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers , 2017, Molecular Cancer Therapeutics.
[8] R. Blamey,et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. , 1997, The Journal of clinical endocrinology and metabolism.
[9] V. Goffin,et al. New concepts in prolactin biology. , 2010, The Journal of endocrinology.
[10] W. Oyen,et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] V. Goffin,et al. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications , 2015, Expert opinion on therapeutic targets.
[12] Kristopher C. Carver,et al. SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. , 2009, Molecular endocrinology.
[13] G. Thurston,et al. Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs , 2017, Molecular Cancer Therapeutics.
[14] Serge K. Lyashchenko,et al. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT , 2016, The Journal of Nuclear Medicine.
[15] M. García-Closas,et al. Prolactin Receptor Expression and Breast Cancer: Relationships with Tumor Characteristics among Pre- and Post-menopausal Women in a Population-Based Case–Control Study from Poland , 2014, Hormones and Cancer.
[16] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[17] J. Humm,et al. Copper-64 trastuzumab PET imaging: a reproducibility study. , 2019, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[18] J. Mulshine,et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] S. Larson,et al. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] P. Cutler,et al. Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] Jason S. Lewis,et al. Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.
[22] J. Humm,et al. 124I-huA33 Antibody PET of Colorectal Cancer , 2011, The Journal of Nuclear Medicine.
[23] Steven P. Larson,et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.